CVS Health Corp (CVS) Shares Sold by Regentatlantic Capital LLC

Cornelia Mascio
Mag 19, 2017

Brokerage houses, on average, are recommending investors to buy CVS Health Corporation (CVS)'s shares projecting a $86.77 target price. The fund owned 152,453 shares of the pharmacy operator's stock after selling 657 shares during the period. $1.13M worth of CVS Health Corp (NYSE:CVS) was sold by Sussman Andrew on Monday, March 13. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/16/2654-shares-in-cvs-health-corp-cvs-acquired-by-doyle-wealth-management-updated.html.

CVS Health Corporation (CVS) performance during the last one year Degraded -22.66 percent, while its year to date (YTD) performance showed a Positive trend of 1.52 percent. Gemmer Asset Management LLC increased its position in shares of CVS Health Corp by 7.6% in the third quarter. Following the sale, the executive vice president now directly owns 41,614 shares in the company, valued at approximately $3,312,474.40. Mercer Capital Advisers Inc. bought a new stake in CVS Health Corp during the first quarter valued at $118,000. Elgethun Capital Management purchased a new position in shares of CVS Health Corp during the fourth quarter valued at approximately $133,000. The stock decreased 3.53% or $2.79 during the last trading session, reaching $76.33. (CARA) stock confirmed the flow of 7.44% with the final price of $17.18. Millennium Mngmt Ltd has 0.11% invested in CVS Health Corp (NYSE:CVS) for 683,354 shares. Price T Rowe Associates Inc. Gemmer Asset Management LLC now owns 1,409 shares of the pharmacy operator's stock worth $125,000 after buying an additional 100 shares in the last quarter. Following the completion of the transaction, the chief financial officer now owns 250,335 shares of the company's stock, valued at $20,197,027.80.

CVS Health Corporation (CVS) shares saw a recent bid of $80.47 and 3.79M shares have exchanged hands in the recent trading session, yielding a -0.72% decline over the past week. The company has also promised to launch more products this year that have greater skin benefits.

CVS has a 1-year high price of $ 102.59 and 1-year low price of $68.44. The stock closing price is now trading upward to its 50 day moving average with change of 1.17%, tumbled to its 20 day moving average with figure of -0.21% and behind its 200 day moving average with value -2.75%.

Riverhead Capital Mgmt Ltd Company has 0.23% invested in CVS Health Corp (NYSE:CVS) for 47,026 shares.

The Average Earnings Estimate for the Current Fiscal quarter is $1.31 per share, according to consensus of 21 analysts.

While considering growth estimates of the company, it has next quarter growth estimates of -0.6% whereas during current quarter it has -0.8% estimations over growth, comparing to the estimations of 0.5% during current year and 8.5% for next year. The stock of CVS Health Corp (NYSE:CVS) has "Neutral" rating given on Thursday, December 17 by Goldman Sachs. However, the company's most recent quarter increase of 3% looks unattractive.

Symantec Corporation (NASDAQ:SYMC) have shown a low EPS growth of -17.50% in the last 5 years and has earnings growth of 81.70% yoy. The company is expected to report EPS as high as $1.33 and as low as $1.29 per share.

The firm also recently declared a quarterly dividend, which was paid on Monday, May 1st. Advisor Prtn Limited Liability Corporation invested in 0.47% or 19,952 shares. A recommendation of 1 or 2 would represent a consensus Buy. There is a large variety of Financial Ratios that can be considered while making an investment decision but here in the case of CVS Health Corporation (CVS), we will discuss a few.

WARNING: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of USA and global trademark & copyright law.

CVS Health Corp (NYSE:CVS) last released its quarterly earnings data on Thursday, February 9th. Maxim Group maintained the stock with "Buy" rating in Wednesday, August 26 report.

In terms of Buy, Sell or Hold recommendations, CVS Corp (NYSE:CVS) has analysts' mean recommendation of 2. Twenty One analysts have issued estimates for CVS Health Corp's earnings. They set a "buy" rating on the stock. Deutsche Bank maintained CVS Health Corp (NYSE:CVS) rating on Wednesday, July 22. Evercore ISI reaffirmed an "outperform" rating and set a $88.00 target price (up from $87.00) on shares of CVS Health Corp in a research report on Wednesday, May 3rd. On Monday, August 24 the stock rating was initiated by H.C. Wainwright with "Buy". Leerink Swann set a $90.00 target price on CVS Health Corp and gave the stock a "buy" rating in a research note on Saturday, March 18th. The shares were sold at an average price of $78.73, for a total value of $1,877,631.77. Accuvest Global Advisors owns 4,820 shares for 0.34% of their portfolio.

In other CVS Health Corp news, CFO David M. Denton sold 95,618 shares of CVS Health Corp stock in a transaction on Friday, March 10th. The shares were sold at an average price of $80.68, for a total value of $7,714,460.24. The disclosure for this sale can be found here.

Now the P/E of CVS Health Corporation stands at 16.69.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE